| LDR | | 04580cmm u2200625 i 4500 |
| 001 | | 000000322635 |
| 003 | | OCoLC |
| 005 | | 20230613114934 |
| 006 | | m d |
| 007 | | cr cn||||||||| |
| 008 | | 220102s2021 dcua ob 100 0 eng |
| 016 | 7 |
▼a 9918332429606676
▼2 DNLM |
| 020 | |
▼a 9780309092395
▼q (electronic bk.) |
| 020 | |
▼a 0309092396
▼q (electronic bk.) |
| 020 | |
▼z 9780309092142 |
| 020 | |
▼z 0309092140 |
| 035 | |
▼a 3133678
▼b (N$T) |
| 035 | |
▼a (OCoLC)1291869449 |
| 040 | |
▼a NLM
▼b eng
▼e rda
▼c NLM
▼d OCLCO
▼d OCLCF
▼d N$T
▼d 248032 |
| 042 | |
▼a pcc |
| 049 | |
▼a MAIN |
| 050 | 4 |
▼a RM301.25 |
| 060 | 00 |
▼a QZ 185 |
| 082 | 04 |
▼a 615.1/9
▼2 23/eng/20221122 |
| 100 | 1 |
▼a March, Andrew,
▼c (Associate program officer),
▼e rapporteur. |
| 245 | 10 |
▼a Innovation in drug research and development for prevalent chronic diseases :
▼b proceedings of a workshop /
▼c Andrew March, Amanda Wagner Gee, Robert Pool, and Carolyn Shore, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Health and Medicine Division, the National Academies of Sciences, Engineering, and Medicine.
▼h [electronic resource] |
| 264 | 1 |
▼a Washington, DC :
▼b The National Academies Press,
▼c [2021] |
| 300 | |
▼a 1 online resource (1 PDF file (xv, 96 pages)) :
▼b illustrations |
| 336 | |
▼a text
▼b txt
▼2 rdacontent |
| 337 | |
▼a computer
▼b c
▼2 rdamedia |
| 338 | |
▼a online resource
▼b cr
▼2 rdacarrier |
| 504 | |
▼a Includes bibliographical references. |
| 520 | 3 |
▼a Investment and innovation in drug research and development (R&D) for highly prevalent chronic diseases has stalled in recent decades, despite half of all Americans living with at least one chronic disease. As a result, prevalent chronic diseases are producing immense health care costs as well as preventable suffering and death. On February 22, March 2, and March 8, 2021, the National Academies of Sciences, Engineering, and Medicine, convened a workshop to discuss barriers to innovation in this space and examine strategies and incentives to support equitable, person-centered drug R&D for prevalent chronic diseases. |
| 536 | |
▼a This activity was supported by contracts between the National Academy of Sciences and Amgen Inc.; Association of American Medical Colleges; AstraZeneca; Biogen; Biomedical Advanced Research and Development Authority; Burroughs Wellcome Fund (Contract No. 1021334); Critical Path Institute; Eli Lilly and Company (Contract No. 4900709231); FasterCures, Milken Institute; Foundation for the National Institutes of Health; Friends of Cancer Research; Johnson & Johnson; Medable, Inc.; Merck & Co., Inc. (Contract No. MRLCPO-21-138769); National Institutes of Health (Contract No. HHSN263201800029I; Task Order No. HHSN26300007): National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, Office of Science Policy; New England Journal of Medicine; Sanofi (Contract No. 65873711); Takeda Pharmaceuticals; U.S. Food and Drug Administration (Grant No. 1R13FD007302-01). Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. |
| 588 | |
▼a Description based on online resource; title from PDF title page (viewed January 7, 2022). |
| 590 | |
▼a WorldCat record variable field(s) change: 082 |
| 650 | 12 |
▼a Chronic Disease
▼x therapy |
| 650 | 12 |
▼a Drug Discovery |
| 650 | 22 |
▼a Translational Research, Biomedical |
| 650 | 0 |
▼a Drug development
▼v Congresses. |
| 650 | 0 |
▼a Chronic diseases
▼x Treatment
▼v Congresses. |
| 650 | 0 |
▼a Pharmaceutical industry
▼x Technological innovations
▼v Congresses. |
| 651 | 2 |
▼a United States |
| 655 | 2 |
▼a Congress |
| 655 | 7 |
▼a Conference papers and proceedings.
▼2 fast
▼0 (OCoLC)fst01423772 |
| 655 | 7 |
▼a Conference papers and proceedings.
▼2 lcgft |
| 655 | 7 |
▼a Actes de congre?s.
▼2 rvmgf |
| 700 | 1 |
▼a Gee, Amanda Wagner,
▼e rapporteur. |
| 700 | 1 |
▼a Shore, Carolyn,
▼e rapporteur. |
| 700 | 1 |
▼a Pool, Robert,
▼d 1955-,
▼e rapporteur. |
| 710 | 2 |
▼a National Academies of Sciences, Engineering, and Medicine (U.S.).
▼b Forum on Drug Discovery, Development, and Translation.,
▼e sponsoring body. |
| 711 | 2 |
▼a Innovation in Drug Research and Development for Prevalent Chronic Diseases
▼d (2021 :
▼c Online) |
| 856 | 40 |
▼3 EBSCOhost
▼u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3133678 |
| 938 | |
▼a EBSCOhost
▼b EBSC
▼n 3133678 |
| 990 | |
▼a 관리자 |
| 994 | |
▼a 92
▼b N$T |